Searchable abstracts of presentations at key conferences in endocrinology

ea0019p99 | Clinical practice/governance and case reports | SFEBES2009

Testosterone replacement therapy in Prader-Willi syndrome with diabetes markedly improves glycaemic control

Muraleedharan V , Rolfe C , Jones TH

Prader-Willi syndrome is characterized by severe hypotonia and feeding difficulties in early infancy, followed in later infancy or early childhood by excessive eating and gradual development of morbid obesity and learning difficulties. Hypogonadism occurs in both males and females, manifested by genital hypoplasia, incomplete pubertal development, and infertility. Type 2 diabetes mellitus is common in obese individuals, most likely secondary to hyperphagia. Diabetes is often d...

ea0029p269 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Testosterone replacement therapy inhibits key enzymes of fatty acid synthesis in mouse liver

Brooke J. , Kelly D. , Akhtar S. , Muraleedharan V. , Jones T.

Fatty liver (Hepatic Steatosis) is common in men with type 2 diabetes mellitus (T2DM). Furthermore there is a high prevalence of testosterone deficiency (up to 40%) in this population. Testosterone replacement therapy (TRT) has been shown to reduce elevated serum liver transaminase levels in hypogonadal men. The testicular feminised (Tfm) mouse exhibits a non-functional androgen receptor (AR) and low circulating testosterone levels. We have previously shown that a high-fat die...

ea0029p273 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Testosterone replacement therapy: a safety audit of clinical practice including men with Type 2 diabetes and cardiovascular disease

Brooke J. , Walter D. , Muraleedharan V. , Jones T.

Hypogonadism is highly prevalent in men with type 2 diabetes (T2D) and/or cardiovascular disease (CVD). Low testosterone levels are associated with CVD risk factors including obesity, insulin resistance, dyslipidaemia and hypertension. Testosterone replacement therapy (TRT) has been shown to have beneficial effects on these parameters; however, safety needs to be verified. An audit of 308 (50% with T2D, 32.1% CVD, 82.8% ED) hypogonadal men (age 59.02±13.23 years; mean bas...

ea0063p124 | Diabetes, Obesity and Metabolism 1 | ECE2019

Management of acute charcot arthropathy

Ahmad F , Yehia S , Devaka F , Muraleedharan V , Sihota S , Abdulla H , Higgins E , Fisher A , Thompson J

Aims/objectives: The aim of this retrospective audit on MANAGEMENT OF ACUTE CHARCOT ARTHROPATHY was to assess the current practice at King’s Mill hospital against the latest National institute of clinical excellence guidelines.Methods: A retrospective audit of 22 patients with diabetes presented with acute Charcot neuro-arthropathy, between January 2016 and August 2018 to the specialist diabetes foot team at KMH. The data was collected from the hosp...